Does REGORAFENIB Cause Neoplasm malignant? 24 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 24 reports of Neoplasm malignant have been filed in association with REGORAFENIB (Stivarga). This represents 0.3% of all adverse event reports for REGORAFENIB.
24
Reports of Neoplasm malignant with REGORAFENIB
0.3%
of all REGORAFENIB reports
12
Deaths
6
Hospitalizations
How Dangerous Is Neoplasm malignant From REGORAFENIB?
Of the 24 reports, 12 (50.0%) resulted in death, 6 (25.0%) required hospitalization, and 1 (4.2%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for REGORAFENIB. However, 24 reports have been filed with the FAERS database.
What Other Side Effects Does REGORAFENIB Cause?
Off label use (1,906)
Fatigue (1,530)
Palmar-plantar erythrodysaesthesia syndrome (1,230)
Diarrhoea (1,221)
Decreased appetite (941)
Asthenia (825)
Death (813)
Dysphonia (702)
Nausea (688)
Pain in extremity (686)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which REGORAFENIB Alternatives Have Lower Neoplasm malignant Risk?
REGORAFENIB vs REGORAFENIB\REGORAFENIB
REGORAFENIB vs RELATLIMAB
REGORAFENIB vs RELPAX
REGORAFENIB vs RELUGOLIX
REGORAFENIB vs REMDESIVIR